

MolMed will attend the 2nd EBMT INTERNATIONAL TRANSPLANT COURSE in Barcelona

Milan (Italy), September, 7 2017 – The 2nd EBMT INTERNATIONAL TRANSPLANT COURSE (8-10 September 2017) begins tomorrow at the Faculty of Medicine at the University of Barcelona. The meeting brings together the European leading experts in the field of bone marrow transplantation and cells therapies.

Once again MolMed will participate in the initiative by sponsoring a scientific update session, scheduled for Friday, September 8, 2017, starting at 13.15.

Speakers will be two internationally renowned Italian researchers, Dr. Chiara Bonini, Head of Unit of the Department of Immunology, Transplantation and Infectious Diseases of the San Raffaele Hospital of Milan, on "Memory stem T cells in longitudinal studies of HSCT and Next Generation Adoptive Cell Therapies" and Professor Fabio Ciceri, Director of the Hematology and Bone Marrow Division of the same hospital who will deal with the topic "Exploiting manipulated DLI after haploidentical HSCT".

Both presentations will cover issues closely related to TK cells, developed and produced by MolMed, for which, under the name of Zalmoxis, the Company received Conditional Release Authorization throughout Europe last year. Zalmoxis is the first immunogene therapy, as patient-specific adjunctive treatment in haplo-identical haematopoietic stem-cell transplantation (HSCT) for adult patients with high-risk haematological malignancies.



PRESS RELEASE

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (Reuters: MLMD.MI).

For further information:

Laura Villa

Investor Relations & Communication Director

MolMed S.p.A.

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Federico Ferrari

Press agent

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991

mobile +39 347 6456873

e-mail: ferrari@secrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..